Post by luxetvox on Nov 10, 2023 17:54:47 GMT
This morning's Bloomberg news feed for Opko had the following headline as the most recent item. It said, "Opko Health: Finl Press Release". The time of the headline was....2:30, which means in the middle of the night. The source was coded 'CFL', which per Bloomberg's glossary indicates Company Filing. Clicking on the headline brought me to another Bloomberg page with a small icon of a document, above which it said 'Media', and below which it said 'Docstory Document ID'. At this point, I knew I was looking at something I've never before seen on Bloomberg. As a comparison, when Opko filed the 10-Q for Q3, a headline showed up saying: "Opko Health, Inc.: 10-Q 2023/09/30". And the source was EDG, meaning Edgar filings.
If I click on the latter (the 10-Q headline), it brings me to a similar page as the mysterious one above, but one which is routine, and recognizable. There is the small icon of a document, above which it says 'Media', and below which it says Edgar Accession Number. Clicking on that pulls up the 10-Q, as expected. There is another way to access such documents on Bloomberg, namely the CF function, which is a listing of all Company Filings. Type CF under the Opko ticker, and you get what you'd expect: the current Q, the current Earnings Call, most recent 8-K. And scrolling down you get documents filed earlier in the year. All normal.
Back to the mystery document. As I said, I can access it from the headline by clicking on that 'Media' icon. Then I wondered if it was also listed under the CF page on Bloomberg, along with all the other aforementioned filings. Yup, there it is. The document is called 'Opko Health Inc: Tear Sheet", and the Type is designated (as it was on the headline that started this rabbit hole dive) 'Finl Press Release'.
So, why am I reconstructing this nonsense for you? Because of what the one page document contained:
Company Overview
OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet patient needs and establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, one of the nation's largest clinical laboratories, with a core genetic testing business and a 300 person sales and marketing team to drive growth and leverage new products, including 4KScore® prostate cancer laboratory developed test and the Claros® 1 point-of-care device, which is capable of in office measurement of PSA within 10 minutes.
Our pharmaceutical business features Rayaldee® (calcifediol), an FDA approved treatment for SHPT in stage 3-4 chronic kidney disease (CKD) patients with vitamin D insufficiency, which was launched in November 2016. Besides nephrology, we have strategic focus on the development of diagnostic and therapeutic agents in urology and endocrinology. Pipelines using the same proprietary platforms, such as the long acting CTP, Reverse-PEGylation, and the Claros® 1 immunoassay system are in various stage of discovery, lead molecule validation, early clinical, clinical, and expanded post marketing indications. We invest in development of low risk proven therapeutic targets and utilize validated technology to expand our diagnostic test menu for unmet medical needs.
We have production and distribution assets abroad, several strategic investments, and an active business development strategy. We expect our future growth to arise from leveraging our proprietary technology, development strengths, and the pursuit of complementary acquisitions and investments.
Stock Overview
Symbol OPK Exchange Nasdaq
Investor Relations
LHA
Yvonne K. Briggs T: 310-691-7100 YBriggs@lhai.com
Market Cap Last Price 52-Week Range
1.04b
$1.34 $1.00 - $2.24
11/08/2023 04:00 PM EST
There is also a list of all senior management, domestic and abroad, from Frost to Arie Gutman (President of API). It includes the only manager making money for the company, one Hans Berner, President OPKO Health Iberoamerica. By the way, as a review, we have two Vice Chairman (Jane, although she isn't a man afaik; and EZ); we have three execs with 'President' titles, EZ, Tony Cruz (President of Transition Therapeutics), and the aforementioned Hans; and three execs with CEO titles (Frost, Bishop, and Damien Burke of Eirgen). Now I know why we need an Executive Vice President, Administration, the highest paid coffee boy in the USA, Steve Rubin; an expert in Administration is clearly essential to keep track of all the titles, employment contracts, salaries, benefits and, well, I'm unsure what else.
The second page has three recent news headlines and their dates (Q3 results, Kidney Week Shindig, and the announcement of the date of Q3 results....nice). Then there is a boiler plate disclaimer at the bottom, in smaller print of course:
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks anduncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, andother risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterlyreports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are theproperty of their respective companies.
So..........clearly bot generated. There is no mention of ModeX, but both EZ and GN are listed among thousands of execs. Then there is mention of the 'core genetic testing business'. Then, the salt in the wound, two mentions of Claros.
But here's my point, does neither the company (perhaps the Exec VP, Administration) nor its IR firm know that this kind of stuff is being put out there is cyberspace, for anyone to be misled? On the other hand, did a bot generate the disclaimer?
It's just another interesting example of how Opko occupies its own special niche in the public company universe, where bad news is bad news, and good news produces near all-time lows in the stock. And nobody cares, because the bots are as active as the humans supposedly running the joint.
If I click on the latter (the 10-Q headline), it brings me to a similar page as the mysterious one above, but one which is routine, and recognizable. There is the small icon of a document, above which it says 'Media', and below which it says Edgar Accession Number. Clicking on that pulls up the 10-Q, as expected. There is another way to access such documents on Bloomberg, namely the CF function, which is a listing of all Company Filings. Type CF under the Opko ticker, and you get what you'd expect: the current Q, the current Earnings Call, most recent 8-K. And scrolling down you get documents filed earlier in the year. All normal.
Back to the mystery document. As I said, I can access it from the headline by clicking on that 'Media' icon. Then I wondered if it was also listed under the CF page on Bloomberg, along with all the other aforementioned filings. Yup, there it is. The document is called 'Opko Health Inc: Tear Sheet", and the Type is designated (as it was on the headline that started this rabbit hole dive) 'Finl Press Release'.
So, why am I reconstructing this nonsense for you? Because of what the one page document contained:
Company Overview
OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet patient needs and establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, one of the nation's largest clinical laboratories, with a core genetic testing business and a 300 person sales and marketing team to drive growth and leverage new products, including 4KScore® prostate cancer laboratory developed test and the Claros® 1 point-of-care device, which is capable of in office measurement of PSA within 10 minutes.
Our pharmaceutical business features Rayaldee® (calcifediol), an FDA approved treatment for SHPT in stage 3-4 chronic kidney disease (CKD) patients with vitamin D insufficiency, which was launched in November 2016. Besides nephrology, we have strategic focus on the development of diagnostic and therapeutic agents in urology and endocrinology. Pipelines using the same proprietary platforms, such as the long acting CTP, Reverse-PEGylation, and the Claros® 1 immunoassay system are in various stage of discovery, lead molecule validation, early clinical, clinical, and expanded post marketing indications. We invest in development of low risk proven therapeutic targets and utilize validated technology to expand our diagnostic test menu for unmet medical needs.
We have production and distribution assets abroad, several strategic investments, and an active business development strategy. We expect our future growth to arise from leveraging our proprietary technology, development strengths, and the pursuit of complementary acquisitions and investments.
Stock Overview
Symbol OPK Exchange Nasdaq
Investor Relations
LHA
Yvonne K. Briggs T: 310-691-7100 YBriggs@lhai.com
Market Cap Last Price 52-Week Range
1.04b
$1.34 $1.00 - $2.24
11/08/2023 04:00 PM EST
There is also a list of all senior management, domestic and abroad, from Frost to Arie Gutman (President of API). It includes the only manager making money for the company, one Hans Berner, President OPKO Health Iberoamerica. By the way, as a review, we have two Vice Chairman (Jane, although she isn't a man afaik; and EZ); we have three execs with 'President' titles, EZ, Tony Cruz (President of Transition Therapeutics), and the aforementioned Hans; and three execs with CEO titles (Frost, Bishop, and Damien Burke of Eirgen). Now I know why we need an Executive Vice President, Administration, the highest paid coffee boy in the USA, Steve Rubin; an expert in Administration is clearly essential to keep track of all the titles, employment contracts, salaries, benefits and, well, I'm unsure what else.
The second page has three recent news headlines and their dates (Q3 results, Kidney Week Shindig, and the announcement of the date of Q3 results....nice). Then there is a boiler plate disclaimer at the bottom, in smaller print of course:
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks anduncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, andother risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterlyreports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are theproperty of their respective companies.
So..........clearly bot generated. There is no mention of ModeX, but both EZ and GN are listed among thousands of execs. Then there is mention of the 'core genetic testing business'. Then, the salt in the wound, two mentions of Claros.
But here's my point, does neither the company (perhaps the Exec VP, Administration) nor its IR firm know that this kind of stuff is being put out there is cyberspace, for anyone to be misled? On the other hand, did a bot generate the disclaimer?
It's just another interesting example of how Opko occupies its own special niche in the public company universe, where bad news is bad news, and good news produces near all-time lows in the stock. And nobody cares, because the bots are as active as the humans supposedly running the joint.